v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Mar. 31, 2026
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of research and development expenses

Three months ended March 31, 

2026

  ​ ​ ​

2025

External clinical development expenses

$

2,483,466

$

1,697,229

Personnel related and stock-based compensation

 

722,257

 

429,418

Other research and development expenses

 

228,040

 

247,492

Total research and development expenses

$

3,433,763

$

2,374,139